A Cell Model Suitable for a High-Throughput Screening of Inhibitors of the Wnt/β-Catenin Pathway
Marina Grimaldi, Abdelhay Boulahhtouf, Corinne Prévostel, Alain Thierry, Patrick Balaguer, Philippe Blache

To cite this version:
Marina Grimaldi, Abdelhay Boulahhtouf, Corinne Prévostel, Alain Thierry, Patrick Balaguer, et al.. A Cell Model Suitable for a High-Throughput Screening of Inhibitors of the Wnt/β-Catenin Pathway. Frontiers in Pharmacology, Frontiers, 2018, 9, pp.1160. 10.3389/fphar.2018.01160. hal-02282710

HAL Id: hal-02282710
https://hal.umontpellier.fr/hal-02282710
Submitted on 10 Sep 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
A Cell Model Suitable for a High-Throughput Screening of Inhibitors of the Wnt/\(\beta\)-Catenin Pathway

Marina Grimaldi\(^1,2,3,4\), Abdelhay Boulahtouf\(^1,2,3,4\), Corinne Prévostel\(^1,2,3,4\), Alain Thierry\(^1,2,3,4\), Patrick Balaguer\(^1,2,3,4\) and Philippe Blache\(^1,2,3,4\)

\(^1\) Institut de Recherche en Cancérologie de Montpellier, Montpellier, France, \(^2\) INSERM, U1194, Montpellier, France, \(^3\) Université de Montpellier, Montpellier, France, \(^4\) Institut Régional du Cancer de Montpellier, Montpellier, France

A constitutive activation of the Wnt/\(\beta\)-catenin pathway is an initiating event in colon carcinogenesis. We developed colon cancer cell models that highlight the non-selectivity of previously described inhibitors of the Wnt pathway and we propose our model as a suitable screening system for inhibitors of the pathway.

**Keywords:** cell models, Wnt/\(\beta\)-catenin pathway, inhibitors, high-throughput screening, colorectal cancer

**RESULTS**

A constitutive activation of the Wnt/\(\beta\)-catenin signaling pathway is admitted as an initiating event of carcinogenesis in at least 90% of colorectal cancers (Giles et al., 2003). This constitutive activity is mostly due to mutations of the APC tumor suppressor that result in the accumulation of \(\beta\)-catenin in the nucleus where \(\beta\)-catenin interacts with TCFs transcription factors to activate the transcription of target genes like c-myc (Sansom et al., 2007). To date, very few molecules targeting the Wnt pathway have been discovered and none has been yet approved for clinical practice (Kahn, 2014). Therefore, there is a great interest in identifying new inhibitors of Wnt signaling for clinical use.

Luciferase-based reporter assays are widely used for studying gene expression at the transcriptional level. Here, we use such a system to set up a high-throughput screening assay for inhibitors of the Wnt/\(\beta\)-catenin signaling pathway by using DLD-1 cells stably transfected with a luciferase TCF reporter plasmid (Veeman et al., 2003). The choice of a good control was critical given that a previous work dedicated to screen new Wnt inhibitors had recently been retracted due to a non-selective inhibition of the firefly luciferase activity (Li et al., 2017). Besides, a reporter system based on mutated TCF binding sites is available, but has a very low basal luciferase activity and is rather a control for a non-specific activation of the Wnt pathway. Here, we developed a genetically modified DLD-1 cell line model expressing the firefly luciferase under the control of the E2F1 promoter, an independent promoter of the WNT pathway.
Two types of available Wnt inhibitors were used in order to validate the model: the tankyrase (TNKS) inhibitors XAV939 (Huang et al., 2009), IWR-1 (Chen et al., 2009) and WIKI4 (James et al., 2012), and the destabilizers of the TCF/β-catenin complex ICRT14 (Gonsalves et al., 2011) and PNU-74654 (Trosset et al., 2006). TNKS acts as an activator of the Wnt/β-catenin signaling by mediating poly-adenosine diphosphate (ADP) ribosylation of AXIN-1 and -2, two key components of the β-catenin destruction complex whose inhibition enhances β-catenin degradation and consequently inhibits the Wnt/β-catenin signaling (Yamada and Masuda, 2017).

XAV939 (Figure 1A), IWR-1 (Figure 1B), and WIKI4 (Figure 1C) specifically inhibited the activity of the Wnt/β-catenin signaling, with an IC50 of 0.13, 0.21 and 0.28 µM, respectively. However, a side activating effect was observed at doses higher than 1 µM as evidenced by the increase of the luciferase activity observed in the control conditions. Besides, both ICRT14 (Figure 1D) and PNU-74654 (Figure 1E) behaved as non-selective inhibitors as evidenced by the inhibition of both Wnt dependent and independent luciferase activities. In addition, PNU-74654 was poorly efficient. To further determine whether the apparent inhibitory effect of ICRT14 on the Wnt independent luciferase activity was due to a toxicity, or not, we evaluated the impact of ICRT14 on cells viability by using the MTT system in parallel with measurement of the luciferase activity. As shown in Figure 1F, ICRT14 again decreased both Wnt dependent and independent luciferase activities in a dose dependent manner but had no significant effect on cells viability.

**MATERIALS AND METHODS**

Luciferase and MTT assays were done as we previously described (Molina-Molina et al., 2008). More details about the methods are available in the Supplementary Material.

**DISCUSSION**

With respects to the use of inhibitors previously reported as specific, studies have concluded that biological activities were
regulated by the Wnt/β-catenin pathway. In the present study, we demonstrate that the destabilizers of the TCF/β-catenin complex ICRT14 and PNU-74654 are unspecific inhibitors of the Wnt/β-catenin pathway. Therefore, to test the implication of the Wnt pathway in a biological mechanism, it seems more rational to use at least one of the specific inhibitors confirmed here. Compared with the original reference system dedicated to test the activity of the Wnt/β-catenin signaling pathway, our method was set-up with an adequate control that lowers the number of false positives resulting from a non-specific inhibition of the luciferase enzymatic activity. For example, using our method points out ICRT14 as a non-specific inhibitor of the luciferase enzymatic activity. Besides, true positives will have to be dose-dependent tested, and their ability to decrease the proliferation of colon cancer cells will have to be evaluated for further potential therapeutic purposes.

REFERENCES


REFERENCES


AUTHOR CONTRIBUTIONS

CP, PhD, and PaB designed the study. CP, PhD, and AT drafted the manuscript. MG, AB, and PhB performed the experimental work.

FUNDING

INSERM, the Institut du Cancer de Montpellier, and Lilly France financially supported this work.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2018.01160/full#supplementary-material

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The reviewer ZD and handling Editor declared their shared affiliation.

Copyright © 2018 Grimaldi, Boulahtouf, Prévostel, Thierry, Balaguer and Blache. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.